A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality

Synthetic lethality between two genes can personalize targeted therapies, where one of them can serve as a biomarker and the other can serve as a target. The choice of genome-wide screening approach as to shRNA or CRISPR, to identify SLIs, needs to be carefully explored. While the availability of approved small-molecule and biologic drugs targeting synthetic lethal interactions enables fast translation to clinics, effective approaches to...